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Abstract
The Collaboration for AIDS Vaccine Discovery/Comprehensive Antibody – Vaccine Immune Monitoring Consortium (CAVD/
CA-VIMC) assisted an international network of laboratories in transferring a validated assay used to judge HIV-1 vaccine
immunogenicity in compliance with Good Clinical Laboratory Practice (GCLP) with the goal of adding quality to the conduct
of endpoint assays for Human Immunodeficiency Virus I (HIV-1) vaccine human clinical trials. Eight Regional Laboratories in
the international setting (Regional Laboratories), many located in regions where the HIV-1 epidemic is most prominent,
were selected to implement the standardized, GCLP-compliant Neutralizing Antibody Assay for HIV-1 in TZM-bl Cells (TZM-
bl NAb Assay). Each laboratory was required to undergo initial training and implementation of the immunologic assay on-
site and then perform partial assay re-validation, competency testing, and undergo formal external audits for GCLP
compliance. Furthermore, using a newly established external proficiency testing program for the TZM-bl NAb Assay has
allowed the Regional Laboratories to assess the comparability of assay results at their site with the results of neutralizing
antibody assays performed around the world. As a result, several of the CAVD/CA-VIMC Regional Laboratories are now in
the process of conducting or planning to conduct the GCLP-compliant TZM-bl NAb Assay as an indicator of vaccine
immunogenicity for ongoing human clinical trials.
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Introduction
The CAVD/CA-VIMC was established in 2006, in part, to
create a global laboratory program for standardized assessments of
antibody responses to viable vaccine candidates for HIV-1 [1]. This
program’s overall goals included expediting the development of an
effective HIV vaccine through the contribution of validated assays,
development of shared Standard Operating Procedures (SOPs),
laboratory capacity building, and quality assurance oversight with
adherence to GCLP guidelines for human clinical trials [2,3]. These
objectives were aligned with the Global HIV Vaccine Enterprise’s
Scientific Strategic Plans released in 2005 and 2010 [4,5]. Toward
this goal, the program placed an emphasis on engaging scientists at
leading international institutions affiliated with potential interna-
tionalvaccinetrialsites.Eightlaboratorieswereselected tocreatean
integrated network of Regional Laboratories, many representing
regions wherethe HIV-1epidemic is most prominent, to implement
the standardized, GCLP-compliant conduct of the TZM-bl NAb
Assay[6].Theselaboratorieswerealsoselected duetotheircapacity
to serve as regional training centers for further assay transfer within
their country/region.
The TZM-bl NAb Assay measures neutralization as a function
of the reduction in Tat-induced luciferase (Luc) reporter gene
expression after a single round of virus infection [6]. The TZM-bl
cell, a HeLa cell clone engineered to express CD4 and CCR5
[7,8], contains integrated reporter genes for firefly luciferase and
Escherichia coli b-galactosidase which are under the control of an
HIV-1 long terminal repeat (LTR) [8], thus permitting sensitive
and accurate measurements of infection. TZM-bl cells are highly
permissive to infection by most strains of HIV, including
molecularly cloned Env-pseudotyped viruses (pseudoviruses).
Pseudoviruses are created in 293T/17 cells by co-transfection
with an Env-expressing plasmid and a backbone plasmid
containing a defective Env gene. The co-transfected 293T/17
cells generate pseudovirus particles that are able to infect TZM-bl
cells, but due to the absence of a complete genome, are generally
unable to produce infectious progeny virions [6]. Expression of the
luciferase reporter gene in TZM-bl cells is induced by the viral Tat
protein following a single round of infection (see Figure 1) [6].
Luciferase activity is quantified by luminescence and is directly
proportional to the number of infectious virus particles present in
the initial inoculum [6].
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30963The TZM-bl NAb Assay has several advantages over other
neutralizing antibody assays (i.e. PBMC assay) [1,6]. Use of a
clonal cell line (TZM-bl) provides enhanced precision and
uniformity [6]. Pseudoviruses offer advantages over uncloned
virus including greater reagent stability and neutralization assay
reproducibility [1,6]. The assay was validated by the CAVD/CA-
VIMC Central Reference Laboratory (CRL, directed by Dr.
David Montefiori, Duke University Medical Center). The
procedures associated with this validated assay have been
developed into centrally controlled SOPs which are utilized by
all CAVD/CA-VIMC laboratories conducting the TZM-bl NAb
Assay.
Figure 1. Pictorial representation of the TZM bl NAb Assay. Briefly, pseudovirus infection of TZM-bl Cells stimulates expression of Luciferase
Reporter gene thereby emitting luminescence (A). When the pseudovirus is neutralized prior to the infection of TZM-bl Cells, the Luciferase reporter
gene is not expressed and no luminescence is emitted (B).
doi:10.1371/journal.pone.0030963.g001
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one of the gold standard assays utilized for the measurement of the
magnitude and breadth of HIV-1 vaccine-elicited neutralizing
antibody responses [9]. As the data generated by testing HIV-1
vaccine-elicited neutralizing antibody responses could be poten-
tially used in support of a licensing application to a regulatory
authority, the laboratories were required by the CAVD/CA-
VIMC to conduct all research under GCLP to ensure that results
were reliable, repeatable, auditable, and comparable between
multiple testing laboratories [2,3,10]. A Central Quality Assurance
Unit (CQAU) was established for the consortium to implement the
TZM-bl NAb Assay in a GCLP-compliant environment. The
CQAU led an initial effort to harmonize existing GCLP guidelines
for consistent management of laboratory operations in support of
clinical trials [11]. These harmonized GCLPs were adopted for the
studies described in this manuscript. To assure equivalent assay
performance between the CRL and Regional Laboratories, the
CAVD/CA-VIMC Operations Core and CQAU (CA-VIMC
Core) developed an Assay Implementation Plan that outlined key
experiments and procedures necessary to revalidate parameters of
the assay in a GCLP-compliant environment. While literature
describes the transfer of a T-cell based assay between laboratories
in GCLP compliance [12,13], this is the first effort, to our
knowledge, of the transfer of neutralizing antibody assay
technology in compliance to GCLP to multiple laboratories for
use in global HIV vaccine clinical trials.
Materials and Methods
Ethics Statement
This study does not involve human subjects. This study utilized
pre-existing, de-identified specimens and was conducted under the
approval of the local Institutional Review Boards (IRBs). The
following IRBs conducted oversight for their respective sites:
Siriraj Ethics Committee (Bangkok, Thailand), Division of Human
Subject Protection, Walter Reed Army Institute of Research
(DHSP-WRAIR) (Bangkok, Thailand), Institutional Review Board
for Chinese Center for Disease Control and Prevention/National
Center for AIDS/STD Control and Prevention (Beijing, China),
University of Witwatersrand – Human Research Ethics Commit-
tee (Human) (Johannesburg, South Africa), HIV/AIDS Research
Committee of the Uganda National Council for Science and
Technology (Kampala, Uganda), Medical Association of Saarland
– Public Corporation Ethics Commission (Sulzbach, Germany),
NARI Ethics Committee (Pune, India), and YRG CARE
Institutional Review Board (Chennai, India). The data were
analyzed anonymously.
Participating Laboratories
As previously mentioned, the CAVD/CA-VIMC consisted of 8
Regional Laboratories (see Table 1). These laboratories were
selected based on their experience conducting antibody assays for
HIV vaccine research, their existing infrastructure to implement
new assay technology, their capacity to serve as regional training
centers for further assay transfer within their country/region, and
their geographic proximity to the HIV epidemic and potential
HIV vaccine clinical trials.
TZM-bl NAb Assay
The TZM-bl NAb Assay described here is a modified version of
the assay described previously [6,14,15]. Serologic reagents to be
tested for neutralizing activity were serially diluted in 96-well flat-
bottom culture plates containing Growth Medium, followed by the
addition of Env-pseudotyped virus that was previously titrated for
optimal infectivity. Freshly trypsinized TZM-bl cells, containing
an optimal concentration of DEAE-Dextran (as determined in
each laboratory), were added to each well following a 45–90 min
incubation period. Following a 48 hr incubation period, culture
medium was removed from each well and replaced with a
luciferase reporter gene assay system reagent (Britelite, PerkinEl-
mer or Brite-Glo, Promega). After a short incubation (minimum of
2 min), lysates were transferred to 96-well plates for measurement
of luminescence in a luminometer. The 50% inhibitory dose (ID50)
was defined as the reciprocal of the serologic reagent dilution that
caused a 50% reduction in relative luminescence units (RLU)
compared to virus control wells after subtraction of background
RLU. Failure to score at least 50% reduction of RLU at any serum
dilution constituted a negative test; this cut-off was established as
being the midpoint in the linear portion of the neutralization curve
(20–80% neutralization). This assay was formally validated for
specificity (,2% false positive rate), precision (values within 3-fold
for 80% of the determinations), linearity (r
2.0.85), range (20–80%
neutralization), lower limit of detection (+3.3 standard deviation
(s.d.) of background), lower limit of quantitation (+10 s.d. of
background), accuracy (within 95% confidence intervals), and
robustness following ICH Q2R(1) [16].
Pseudovirus Preparation
Pseudoviruses were manually prepared at Duke University
Medical Center (Durham, NC USA) or at the Institut fu ¨r
Biomedizinische Technik (IBMT) (Sulzbach, Germany). 293T/
17 cells (American Tissue Culture Collection) were seeded
(3610
6–5610
6) in a T-75 cm
2 tissue culture flask containing
Growth Medium and incubated 20–24 hours at 37uC/5% CO2.
The following day, transfection complexes were formed by
Table 1. CAVD/CA-VIMC Regional Laboratories that completed the Assay Implementation Plan.
Laboratory Principal Investigator(s) Location
Armed Forces Institute for Research Medical Sciences (AFRIMS) Dr. Mark de Souza, Dr. Victoria Polonis Bangkok, Thailand
Fraunhofer Institut fu ¨r Biomedizinische Technik (IBMT) Dr. Hagen von Briesen Sulzbach, Germany
Makerere University – Walter Reed Project (MUWRP) Dr. Fred Wabwire-Mangen, Dr. Victoria Polonis Kampala, Uganda
National AIDS Research Institute Dr. Ramesh Paranjape Pune, India
National Center for AIDS/STD Prevention and Control (NCAIDS), China CDC Dr. Yiming Shao Beijing, China
National HIV Repository and Bioinformatic Center/Siriraj Hospital Dr. Ruengpung Sutthent, Dr. Victoria Polonis Bangkok, Thailand
National Institute for Communicable Diseases (NICD) Dr. Lynn Morris Johannesburg, South Africa
Y.R. Gaitonde Centre for AIDS Research and Education (YRG CARE) Dr. Suniti Solomon, Dr. Pachamuthu Balakrishnan Chennai, India
doi:10.1371/journal.pone.0030963.t001
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reporter gene and a backbone plasmid containing a defective
Env-gene along with FuGENE 6 reagent (Promega, USA) and
Dulbecco’s Modified Eagle Medium (Gibco). The transfection
complexes were allowed to incubate for 30 minutes at room
temperature (18u–25uC). The complexes were then added to the
flask of 293T/17 cells and incubated at 37uC/5% CO2 for 3–
8 hours. Following a change of media after the 3–8 hour
incubation, the cells were incubated at 37uC/5% CO2 for an
additional 48–72 hours. The virus-containing media was then
harvested from the flasks and filtered through a 0.45 mm filter, to
eliminate cell debris. The concentration of FBS was brought up to
20% in the virus-containing medium and the medium aliquoted
and frozen at 280uC.
Tissue-Culture Infectious Dose Assay (Pseudovirus
Titration)
Pseudovirus stocks were plated in quadruplicate and serially
diluted in Growth Medium. Freshly trypsinized TZM-bl cells were
added to the plate in GM containing an optimized concentration
of DEAE-Dextran. The plate was incubated for 48 hours at 37uC/
5% CO2. Following the incubation period, culture medium was
removed from each well and replaced with a luciferase reporter
gene assay system reagent (Britelite, PerkinElmer or Brite-Glo,
Promega). After a short incubation (minimum of 2 min), lysates
were transferred to 96-well plates for measurement of lumines-
cence in a luminometer. The recommended virus dilution to use in
the TZM-bl NAb Assay was calculated to ensure a standardized
virus dose in the assays.
Laboratory Assay Implementation Plan
The goal of the Implementation Plan was to ensure that all
laboratories within the Consortium were performing the TZM-bl
NAb Assay in a GCLP-compliant environment and were
achieving comparable results. The Implementation Plan consisted
of four Phases and each laboratory was required to successfully
achieve pre-determined criteria in each Phase in order to complete
the Plan. Phase I of the Implementation Plan focused on the initial
training and transfer of the assay technology to each of the
laboratories. Phase II outlined a series of procedures and
experiments that aimed to implement and optimize the TZM-bl
Nab Assay in the laboratories. Items such as cell maintenance and
establishment of cell banks, equipment installation and validation,
and determination of optimal concentrations for key reagents were
addressed in this phase. During Phase II, the CQAU also
conducted an initial site-visit to each laboratory and provided
GCLP training to the laboratory staff [11]. The experiments
detailed in Phase III of the Implementation Plan focused on the
local revalidation of the assay through the analysis of robustness
and precision. As a part of this phase, the laboratories were
required to enroll in the formal Global Proficiency Testing
Program for the TZM-bl NAb Assay administered by the CQAU
[15]. The final phase, IV, consisted of a formal GCLP audit led by
an auditor external to the CAVD/CA-VIMC CQAU with
associated corrective actions and preventative actions (CAPA).
The laboratories were also required to conduct trend analysis on
control values and other key parameters that measure quality in
the laboratory. For all phases, acceptance criteria were determined
by the CA-VIMC Core based on the previous validation of the
TZM-bl NAb Assay. The Plan was formalized into a CAVD/CA-
VIMC Central SOP to ensure that each laboratory performed the
identical set of experiments and followed the same procedures.
The laboratories were required to submit the data from each
Phase to the CA-VIMC Core for review and approval. Following
the completion of all phases of the Implementation Plan, the CA-
VIMC Core issued an Endorsement document to the laboratory
stating that the laboratory could perform the TZM-bl NAb Assay
in a GCLP-compliant manner for the CAVD. The Endorsement
was valid for one year and was contingent upon the laboratory’s
successful completion of the semi-annual Global Proficiency
Testing Program [15]. Formal GCLP audits were subsequently
conducted annually for CAVD/CA-VIMC-funded Regional
Laboratories and successful completion led to the re-endorsement
of the laboratory by the CA-VIMC Core.
Data Analysis
All ID50 values were calculated using a formally validated Excel-
based macro or web-based Nab tool [17] that utilizes average virus
and cell control RLU values as well as duplicate test well RLU
values to calculate the neutralizing antibody titer as a function of
the reduction of luciferase reporter gene expression. All means,
standard deviations (s.d.), and r
2 values were calculated using
Microsoft Excel formulas. Percent coefficient of variation (%CV)
was calculated by dividing the s.d. by the mean and multiplying by
100. For the initial on-site competency testing, values within 3-fold
of the established truncated means (the highest and lowest ID50
values were excluded from the mean calculation for each serologic
reagent/pseudovirus) were judged to be acceptable. The fold
difference between the laboratory and the established mean was
calculated by dividing the laboratory value by the mean value:
values between 1/3-fold and 3-fold of the mean were considered
acceptable.
Results
Initial Training
The CA-VIMC Operations and CRL developed an assay
training program for visiting scientists. At least one key laboratory
member from each laboratory was required to successfully
complete this training at the CRL (one Regional Laboratory sent
two individuals to complete training at a CAVD/CA-VIMC
formally-endorsed Regional Laboratory, due to cost and time
considerations). This training program followed a central assay
training SOP which outlined a series of phases including the
reading and understanding of assay SOPs, assay observation, assay
performance with supervision, assay performance without super-
vision, and an initial competency test. The typical duration for the
training program was four weeks and consisted of training on
sterile technique, cell culture, pseudovirus preparation and
titration (TCID assay), the TZM-bl NAb Assay, and data analysis.
Each trainee was required to independently perform a competency
test and meet pre-determined acceptance criteria prior to formal
completion of the training program. Successful completion of the
competency assessment required the trainee to achieve results
within 3-fold of the reference values for at least 80% of serologic
reagent/pseudovirus combinations.
Assay Technology Transfer to Regional Laboratory
In preparation for implementing the assay on-site, the CAVD/
CA-VIMC Operations partnered with each laboratory for the
coordination, acquisition, and procurement of necessary assay
reagents, cell lines, and equipment prior to, or during the assay
training program. Following completion of the training program,
the trainees were responsible for importing the Pseudovirus
Titration and TZM-bl NAb Assay technologies to their laboratory
and training the other laboratory personnel. The trainees were
encouraged to practice performing the assay on-site with existing
specimens in order to increase confidence in the procedure and
Technology Transfer in GCLP for Clinical Trials
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communication with each site to assist in reviewing assay data for
acceptability and troubleshooting of any problems encountered.
GCLP Compliance
The trainees were also encouraged to select areas of their
laboratory that could be converted and dedicated to the conduct of
GCLP compliant assays. Due to the relative novelty of GCLP
principles at the onset of the Consortium, the CQAU worked with
each site to introduce GCLP concepts and strategies and ensure
that each laboratory was aware of the sponsor-driven requirements
and expectations involved with GCLP implementation
[2,3,10,11]. In accordance with GCLP compliance, the CQAU
asked each laboratory to designate an individual to serve as the
site-specific Quality Assurance (QA) Coordinator. The QA
Coordinator was responsible for implementing on-site CAVD/
CA-VIMC Central SOPs directing the conduct of assay,
equipment, management, training, data management, and reagent
preparation procedures for the conduct of the TZM-bl NAb Assay
in compliance to GCLP. To ensure that the QA Coordinator was
knowledgeable of current GCLP guidelines, the CQAU encour-
aged QA Coordinators to attend formal GCLP training seminars
[2,3]. To ensure the delivery and receipt of Central SOPs, the
CQAU utilized a Microsoft Sharepoint-based web portal for the
secure distribution of Central SOPs to the QA Coordinator at
each laboratory and devised a feedback mechanism whereby the
QA Coordinator would confirm receipt of the SOPs via facsimile
or email transmission to the CQAU. Additionally, the QA
Coordinator was responsible for the local oversight of the quality
program as it related to CAVD/CA-VIMC projects. Ideally, the
QA Coordinator was independent from the conduct of any TZM-
bl NAb Assays; however, in cases of limited laboratory capacity or
budgetary constraints, laboratory personnel involved in the
conduct of assays were allowed to serve as the QA Coordinator
provided he or she did not conduct assays for the CAVD/CA-
VIMC. The CQAU also assisted the laboratories with the
development and refinement of site-specific SOPs that covered
general equipment usage and maintenance, facility maintenance,
reagent acquisition, labeling, and maintenance, quality assurance
systems, management processes, specimen management and
transportation, and data management and storage procedures.
Additionally, the CQAU assisted the laboratories in assembling
personnel/training records, disaster recovery plans, quality
management plans, reagent inventories, auditing processes, annual
competency assessments, and change control processes, all in
support of the establishment of GCLP compliance. The CQAU
provided templates and examples of the documents to the
laboratories as reference in developing their own procedures.
TZM-bl Cell Culture and Maintenance
The laboratories were required to create both Master Archive
and Master Working Stocks of cryopreserved cells in order to
preserve the integrity of the cell line. In order to assess the ability
to properly maintain cell lines in culture without contamination,
the laboratories were required to perform quality control testing
for Mycoplasma contamination at weeks 0, 2, 4, 8, 12, 18, and 24 of
culture, yielding negative test results for the entire duration to
assure the quality of the stocks. Each Regional Laboratory
conducted testing via on-site utilization of a commercially
available Mycoplasma detection kit or submission of cells to a third
party Mycoplasma testing facility. The results were required to be
submitted to the CA-VIMC Core for review and approval. Based
on the data submitted, none of the laboratories experienced
Mycoplasma contamination of the Master Archive Stocks or the
Master Working Stocks.
Luminometer Installation and Qualification
The proper installation and validation of the luminometer was
critical as it is a key piece of assay equipment. The initial
installation, operation, and performance qualifications were
performed by a service representative from the purchasing
company. In order to monitor the performance of the instrument
over time, the CQAU purchased and distributed a National
Institute of Standards and Technology (NIST)-traceable Lumi-
nometer Reference Microplate to each laboratory from Harta
Instruments, Inc. The plate utilizes a lithium ion battery and
consists of a series of eight wells, each emitting varying levels of
luminescence. The luminometer performance baseline reading
was established by averaging the RLU values for each well over 20
individual plate runs in each laboratory. The performance of the
luminometer was assessed on a monthly basis through comparison
of monthly runs to the baseline readings in order to analyze the
precision of the instrument (see Figure 2). Each reading had to be
within 10% of the established mean value for the well in order to
pass. Readings outside of 10% of the established mean value were
required to be addressed with documentation and corrective
action which included luminometer service/re-calibration. Re-
gional Laboratories were instructed to re-establish the baseline
readings following annual calibration of the reference plate.
Determination of the Optimal Concentration of DEAE-
Dextran
DEAE-Dextran is a polycationic reagent that enhances the
infectivity of the pseudoviruses [6]. The polycation counters the
repulsive electrostatic forces between the virus and cells surface
without affecting antibody binding and neutralization. However,
DEAE-Dextran from different sources and different lots may
exhibit substantial variability in potency and cell toxicity. This
reagent can be toxic to TZM-bl cells at too high of a
concentration. Therefore, it is imperative that the reagent be
titrated to determine an optimal concentration for use in the assay.
After acquisition of each lot of DEAE-Dextran by the laboratory, a
stock was prepared and titrated using two pseudoviruses following
a Central SOP. The laboratories were required to demonstrate
that the optimal concentration that was selected for use in the
laboratory did not exhibit toxic effects to the TZM-bl cells (see
Figure 3).
Pseudovirus Titration
Pseudoviruses used in the Assay Implementation Plan were
created either by the CRL or by the CAVD/HIV Specimen
Cryorepository (HSC) at the Fraunhofer IBMT (Sulzbach,
Germany). Following preparation and prior to distribution, each
pseudovirus was titrated and assigned a recommended dilution for
use in the TZM-bl NAb Assay; however, subsequent tests have
shown that the optimal dilution of virus to use may be laboratory-
dependent due to differences in cell stocks, reagent vendors, etc. In
order to examine the laboratory’s ability to titrate the virus and
calculate the correct virus dose for use in the TZM-bl NAb Assay,
the laboratory was required to titrate two different pseudoviruses
in TZM-bl cells using the TCID Assay. In order to pass this stage
of Phase II, the laboratory was required to calculate the correct
virus dose for use in the TZM-bl NAb Assay by determining the
corresponding virus dilution based on the luminescence data from
the TCID assay. The selected dilution should not have shown any
evidence of cell killing in the assay. Additionally, to address
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TCID assay were required to have a %CV of less than 10% for at
least 80% of the replicate wells (pre-set criteria). It took
laboratories an average of 1.4 attempts (s.d. 0.6) to pass the
criteria pre-set in the Plan. Data for the average %CV between the
replicate wells of pseudovirus titrations that passed are shown for
each laboratory in Figure 4.
Neutralization Assays
Neutralization assays were conducted using the optimal
concentration of DEAE-Dextran and standard dose of pseudo-
viruses derived from the previous experiments. The laboratory was
required to assay five serologic reagents against two different
pseudoviruses. The following pre-defined acceptance criteria
(listed in the Central SOP) were used to judge the quality of the
Figure 2. Example of a luminometer validation curve. Each month the values of a NIST-traceable-calibrated validation plate are plotted on a
graph. The graphs are then superimposed and the values must remain within 10% of the established baseline (mean of the 20 initial runs).
doi:10.1371/journal.pone.0030963.g002
Figure 3. Example of a DEAE-Dextran titration curve using two pseudoviruses. The optimal concentration of DEAE-Dextran (x-axis) to use
in the TZM-bl NAb Assay is calculated by selecting a concentration lower than the concentration yielding the peak RLU values on both titration curves
of two pseudoviruses (in this instance QHO692.42, CAAN5342.A2). By picking the concentration lower than the peak, one avoids potential cell toxicity
that may result with the use of other pseudoviruses. The vertical dotted line in the graph represents the concentration of DEAE-Dextran that
maximizes the infectivity of the pseudovirus without being toxic to the TZM-bl cells.
doi:10.1371/journal.pone.0030963.g003
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times the average RLU for the cell control wells; 2) the %CV of
the virus control wells is #30%; 3) the %CV of the sample wells is
#30% for sample dilutions yielding at least 40% neutralization; 5)
the neutralization curve is sigmoidal and approximately linear
around 50% (example shown in Figure 5); and 6) the TZM-bl cells
look healthy and are not subjected to analyte toxicity or virus-
induced cell killing. As an additional measure for acceptability, the
r
2 value for the linear portion of the neutralization curve was
calculated. Based on the validation data, the r
2 value of the linear
portion of the neutralization curve between 20% and 80% should
be $0.85. While there were instances (11 out of 80) in which
neutralization curves did not reach 80% (4 with no neutralization,
7 with partial neutralization under 80%), those that showed partial
neutralization (,80%) had r
2 values for their linear portions that
were .0.85. All laboratories successfully passed this stage of the
Plan.
Initial Site-Visit by CQAU
The CQAU conducted an initial site-visit to each of the
Regional Laboratories to examine the level of pre-existing
compliance to GCLP and laboratory set-up. Each visit lasted 2–
3 days and included the examination of items in the laboratory
such as: facilities and equipment, personnel, specimen manage-
ment, reagent acquisition, labeling, and maintenance, operator
training and competency, quality assurance program, data
management and information technology (IT), and archives.
The CQAU also conducted GCLP training at the sites in order to
Figure 4. Average %CV of the replicate wells for the virus titrations that achieved ‘‘pass’’ criteria. The %CV of replicate wells was
required to be lower than 10% at least 80% of the time.
doi:10.1371/journal.pone.0030963.g004
Figure 5. Example of Neutralization Curve. The neutralization curve depicts the linear portion of the curve between 20% and 80%
neutralization.
doi:10.1371/journal.pone.0030963.g005
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[2,3,10,11]. Additionally, the CQAU discussed expectations of the
laboratory with the local QA Coordinator and answered queries
regarding the project. The CQAU composed a report of the
laboratory visit that included suggestions for corrective actions to
implement in order to better comply with GCLP.
Initial On-site Competency Evaluation
The CA-VIMC Operations developed and implemented a
competency testing program for the TZM-bl NAb Assay to
ensure that the assay was being performed properly at each
laboratory. Following a study plan, the CRL prepared and
assembled competency test kits containing 10 blinded serologic
reagents and 5 pseudoviruses. Each laboratory received the study
plan, testing instructions, and a competency test kit to be
performed on-site by the laboratory technician who received
training at the CRL. The laboratories completed the competency
evaluation and submitted their results to the CA-VIMC Core
using a standardized data report. Competency test reference ID50
values were established by measuring the truncated mean for all
data points. Neutralizing antibody ID50 values measuring within
3-fold of the truncated mean ID50 values, for at least 80% of the
serologic reagent/pseudovirus combinations, were deemed ac-
ceptable. The average percentage correct (value for serologic
reagent/pseudovirus combination within 3-fold of established
mean) was 95.4% (s.d. 7.4)(n=7; One laboratory was allowed to
use the proficiency testing kit to serve also as their competency
evaluation due to time constraints; therefore, their values were
judged against the gold-standard reference values of the
Proficiency Testing Program [15]). Individual performance
reports were distributed to each laboratory noting the test results
and suggesting areas of improvement based on examination of
the raw data. As a further measure of how close the data were to
the established truncated means, each laboratory’s experimental
ID50 values were compared to the corresponding mean ID50
values and a ‘‘fold-difference’’ was calculated by dividing the
experimental value by the mean. The average of the ‘‘fold-
differences’’ was then calculated and is graphed in Figure 6. The
objective of using the average ‘‘fold-difference’’ is to determine
how close a laboratory’s values were to the mean values across all
serologic reagent/pseudovirus combinations.
Robustness Experiments
Robustness experiments were conducted by each laboratory to
determine the effect of varying either the optimal virus dose or the
optimal cell concentration for use in the TZM-bl NAb Assay.
Previous validation data suggests that varying the input virus dose
over a 100-fold range has little effect on assay sensitivity, i.e., the
ID50 values of each serologic reagent differed by ,3-fold (data not
shown). The laboratory chose one previously titrated pseudovirus
to conduct five parallel experiments examining the effect of
pseudovirus dose on the neutralization by five serologic reagents.
Experiments utilized the optimal dose of pseudovirus, as derived
above, three times the optimal dose, ten times the optimal dose,
one-third of the optimal dose, and one-tenth of the optimal dose.
Results were submitted to the CA-VIMC Core for verification.
Passing criteria indicated that positive neutralization curves should
be approximately linear between 20% and 80% neutralization. As
stated above, for curves that did not reach 80% neutralization, the
CA-VIMC Core deemed the data acceptable using the criteria
stated in the Central SOP.
To analyze the effect of varying TZM-bl cell concentration, five
parallel experiments were conducted utilizing one previously
titrated pseudovirus assayed against 5 serologic reagents. The
experiments were identical except for the amount of TZM-bl cells
that were used. The laboratory examined the effect of using twice
the optimal number, four times the optimal number, one-half of
the optimal number, and one-fourth of the optimal number of cells
and compared that to the neutralization ID50 values generated in
the assay using the optimal number of cells. The laboratory was
required to examine the quality of the cells via microscopic
examination and the results of the experiment from the optimal
cell concentration experiment had to be within 3-fold of the results
derived in the neutralization assays described in Phase II. As a way
to assess the effect of increasing or decreasing the number of cells
that are placed into the assay, each laboratory’s ID50 values were
Figure 6. Average fold difference between laboratory values and means during initial on-site competency testing. Laboratories were
required to achieve a relative ID50 value within 3-fold of the mean ID50 value (established from CRL and all other participating laboratories) for a
minimum of 80% of reagent/pseudovirus combinations. Only 7 of the laboratories used the identical batch of competency test kits. The other
laboratory used a similar kit from the Proficiency Testing program and was able to achieve the pre-determined pass/fail criteria for the program (data
not shown).
doi:10.1371/journal.pone.0030963.g006
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of the other ID50 values that were calculated based on the
conditions listed above. As seen in the graph, the larger the
deviation from the optimal cell number, the more variation exists
between calculated ID50 values (see Figure 7).
Specificity
The presence of false positives in the TZM-bl NAb Assay could
confound analyses performed to judge the potential efficacy of
vaccine candidates. Thus, the laboratories were required to
calculate the rate of false positives using the TZM-bl NAb Assay
in their laboratory. The laboratory was required to assay 10
known HIV-1 seronegative serum samples against a well
characterized pseudovirus (SF162.LS). The false positive rate
established by the laboratory was required to be less than 10% in
order to pass. All laboratories demonstrated a false positive rate of
less than or equal to 10% (data not shown).
Precision
Intermediate precision is defined by the variations within
laboratory; specifically, between operators, assays, and assay dates
[16]. Each laboratory was required to assess inter-operator
variability (identical assays run by two different operators on the
same day), inter-assay variability and intra-operator variability
(identical assays run by the same operator at different time points).
The calculated ID50 values between assays and/or operators were
required to be within 3-fold at least 80% of the time. Figure 8
shows the average %CV between the ID50 values generated in the
inter-operator experiments (top) and inter-assay experiments
(bottom).
Proficiency Testing Program
The first Standardized Proficiency Testing Program for the
TZM-bl NAb Assay was pioneered by Duke University Medical
Center in 2005 and formally implemented in 2009 through
collaborations with National Institutes of Health/Division of AIDS
(NIH/DAIDS) and the CAVD. The program enabled the
comparison of each laboratory’s results using identical test kits
[15]. Each CAVD/CA-VIMC Regional Laboratory is required to
enroll in the program and successfully complete assessments every
6 months. Furthermore, the CQAU mandates that the laboratory
rotate the technician performing the proficiency testing to provide
a more accurate assessment of the entire laboratory’s performance
over time. All Regional Laboratories have successfully achieved a
passing score of at least 83% to date.
Formal GCLP Audit
As a measure of the laboratory’s compliance to GCLP, the
CQAU conducted a formal audit of each laboratory with the
presence of an external auditor to eliminate bias. The audit was
conducted using a Master Audit Plan and Checklist that was
developed as a result of harmonization efforts of GCLP guidelines
[11]. The audit covered topics such as facility, equipment,
organization, personnel, SOPs, quality program, data handling
and integrity, IT, reagent acquisition, reagent labeling, reagent
maintenance, and archives. Additionally an in-process audit of the
TZM-bl NAb Assay was conducted to ensure that the practices were
compliant with the Central SOP. Following the audit, the laboratory
was given the audit report along with an audit report response form
to which it was required to provide corrective action responses to
findings of the audit within 20 business days. The CQAU then
reviewed theresponsesfromthelaboratoryand followedupwithany
additional items to be addressed. The rectification of common
findings that were reported at the initial site-visit (lack of a functional
Quality Management Plan, reagent bridging procedure, document
archival process/facility, Disaster Recovery Plan, and processes for
ensuring the integrity of IT systems) was verified by the CQAU
before closing the formal audit process.
Figure 7. Results from robustness experiments. Average fold difference between ID50 values calculated from robustness experiments that
varied the number of cells that were used in the assay. Assays were performed using the optimal cell number, twice the optimal cell number, four
times the optimal cell number, one-half of the optimal cell number, and one-quarter of the optimal cell number. The ID50 values for each condition
were required to remain within 3-fold of the ID50 values generated by the optimal cell number.
doi:10.1371/journal.pone.0030963.g007
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As an ongoing activity for each laboratory, analysis and
trending of certain assay-related quality indicators was required.
Each laboratory established positive controls for the TZM-bl NAb
Assay. Fluctuating positive control ID50 values could signal
potential variation within the assay and would result in the need
for troubleshooting. The laboratories were required to monitor
positive control data generated from each experiment over time
Figure 8. Results from precision experiments: inter-operator and inter-assay. (A) Results show the %CV between the ID50 values generated
by two operators carrying out the identical experiment on the same days. Each point represents one sample/pseudovirus combination. (B) Results
show the %CV between ID50 values generated from identical experiments conducted by the same operator on 3 different days. Each point represents
one sample/pseudovirus combination.
doi:10.1371/journal.pone.0030963.g008
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the trending of average cell and virus control well values were also
recommended to the laboratories. During the annual audit, the
CQAU reviews the trending of quality indicators, which are
monitored by the local QA Coordinator, and are performed by the
site throughout the year under standard workload conditions.
Endorsement
Following successful completion of all Phases of the Implemen-
tation Plan, the CA-VIMC Core provided a report to each of the
laboratories that summarized the analysis of the submitted
Implementation Plan data. Upon the successful completion of
the audit and ensuing audit issues/responses, an Endorsement was
issued to each of the laboratories that stated the laboratory’s ability
to conduct the TZM-bl NAb Assay in a GCLP-compliant
environment for the CAVD. The Endorsement was valid for
one year and was issued under the contingency that the laboratory
continue to subscribe to and successfully complete the Proficiency
Test as administered by the TZM-bl Standardized Proficiency
Testing Program and also that the laboratory successfully
complete an annual audit by the CQAU.
Average Time for Implementation Plan Completion
All Regional Laboratories successfully completed the steps
outlined in the Implementation Plan. On average, the time
required for the laboratories to complete all of the phases was 12.8
months (s.d. 9.4). The shortest amount of time required for
completion of the Plan was 6 months.
Discussion
The assays and requirements outlined above represent critical
aspects of the transfer of the TZM-bl NAb Assay to Regional
Laboratories in a GCLP-compliant environment. This Program
demonstrated that successful technology transfer was attainable
across physical and cultural barriers in the global setting. It was
imperative that the laboratories involved in the technology transfer
perform revalidation experiments to document and prove that the
locally-imported assay performed equivalently to the original
validated assay. This assay has become widely used for the
evaluation of the immunogenicity of candidate vaccines in Phase
I/II clinical trials.
All laboratories successfully completed the Implementation Plan
and were formally endorsed by the CA-VIMC to perform the
TZM-bl NAb Assay for human clinical trials on behalf of the
CAVD. However, there were some challenges that were
encountered while working with laboratories in the international
setting with respect to the initial technology transfer and
completion of the Implementation Plan. The CA-VIMC program
originally planned for the training of one key laboratory member
at the CRL at program initiation. However, there were
unanticipated delays in training program participation due to
the lengthy process (e.g. average 8 months) associated with
obtaining the required US visa authorization. During this interim
period, the laboratories planned to obtain key reagents and
equipment such that the assay implementation could begin
immediately following the extensive training at the CRL.
However, some sites faced challenges in obtaining local govern-
ment approval for the utilization of funding as well as the
importation of key reagents and equipment. For this reason, many
of the trainees could not immediately begin assay implementation
at their respective sites. Moreover, these Regional Laboratories
were originally selected based on their extensive HIV vaccine
research experience and affiliation with potential international
vaccine trial sites. However, some of these laboratories were
relatively inexperienced in the study of neutralizing antibodies in
GCLP compliance, which posed initial challenges with assay
design and quality control as well as data interpretation. In
response to these challenges, the CA-VIMC Operations provided
individualized technical support and oversight through close
monitoring and frequent communication. Additionally, the CRL
provided assay training to additional members of Regional
Laboratories that requested further assistance; and, in some
instances the CA-VIMC Operations provided training on-site. As
far as general laboratory compliance to GCLP, there were several
common findings among the laboratories that were identified
during the initial site-visit by the CQAU. Lack of a functional
Quality Management Plan, reagent bridging procedure, archival
facility/process, Disaster Recovery Plan, and procedures for
ensuring IT integrity were noted at a majority of the sites. The
CQAU worked with each laboratory by defining expectations and
also providing templates of documents that could be used to satisfy
the requirements. All deficiencies identified at the initial site visit
were corrected and verified by the CQAU prior to endorsing the
laboratory.
In addition to these logistical and technical issues, language
barriers were a challenge in several of the countries. The CQAU
had the centrally-distributed SOPs professionally translated into
several different languages. Furthermore, it was necessary to
translate site-specific SOPs from their native languages into
English to assure these processes and documentation were
adherent to GCLP guidelines. Similarly, the CA-VIMC Core
realized that formats for recording dates were different among the
Regional Laboratories. To eliminate confusion between date-
recording systems, the CQAU required all dates recorded for
Consortium-related work to be notated, ‘‘dd/MMM/yy’’. Addi-
tionally, one site followed the Buddhist calendar, where recorded
dates are exactly 543 years ahead of the Gregorian calendar. Thus
it was decided that all laboratories must record year dates
according to the Gregorian calendar for consistency.
There were also challenges with meeting some of the acceptance
criteria stated in the Implementation Plan which were adopted
from the original validation of the TZM-bl NAb Assay. The
validation demonstrated that the neutralization curves obtained
for potent serologic reagents against well-established pseudoviruses
reached 80% neutralization. Since the exact serologic reagent/
pseudovirus combination was not specified by the CA-VIMC Core
to the Regional Laboratory for use in conducting the neutraliza-
tion assays, the combinations that were selected did not always
reach 80% neutralization. Failure to achieve 80% neutralization is
not necessarily indicative of a failed assay or poor assay technique
as there are some serologic reagents that do not generate 80%
neutralization against the selected viruses. Thus, in hindsight, the
analysis of neutralization curves for linearity between 20–80% is
not an effective indicator of assay performance. Additionally, a few
laboratories had difficulty selecting the optimal concentration of
DEAE-Dextran for use in the assay. While the concentration most
often selected by the laboratories was the one that yielded the
highest RLU for a particular pseudovirus, the laboratories were
instructed to select a slightly lower concentration to avoid possible
toxicity to the cells. Although laboratories were trained on how to
properly select the optimal concentration, the CA-VIMC Core
attributed this common issue to the quality of the SOP. To remedy
this situation, the SOP was revised and the CA-VIMC Core
provided technical support, reviewed each laboratory’s data,
provided multiple examples, and solicited laboratory feedback to
ensure the laboratories knew how to properly select an optimal
concentration. Finally, the laboratories had problems with the
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each dilution had to be within 10 %CV at least 80% of the time.
Specifically, there was greater variation in the RLU values among
the four replicates at very high and very low virus dilutions in the
titration plate. Low dilutions (i.e. 1:10, 1:50) yielded very high and
variable RLU values; thus raising the %CV. On the other end, at
very high dilutions (i.e. 1:3,906,250, 1:19,531,250), the RLUs are
very low and very minor changes could still have a large effect on
the %CV. While many of the laboratories had to repeat particular
pseudovirus titrations, they all were eventually able to pass the pre-
set criteria of 10 %CV at least 80% of the time.
As a result of the efforts to standardize the conduct of the TZM-
bl NAb Assay in a GCLP-compliant environment, endorsed
laboratories are now in a position to function as regional centers to
conduct the assay for current and future clinical trials. Addition-
ally, the endorsed laboratories are now serving as training centers
for both assay related tasks and for GCLP compliance. As the
popularity of the TZM-bl NAb Assay spreads, it is crucial that a
structure of regional testing and training centers exist so that
clinical trial research can be conducted in the areas where the
clinical trials occur [11,12,18]. To date, five of the laboratories
have already or will soon test samples for Phase I and/or II clinical
trials in their region. Additionally, the laboratories can also use
their expertise in the TZM-bl NAb Assay and GCLP to solicit and
procure additional sources of funding for future projects. This
becomes important as more research sponsors are mandating
laboratory compliance to national/international standards and
regulations as a contingency for funding. This program also serves
as a model to implement newer HIV neutralization assays. Within
the CA-VIMC, efforts are already underway to transfer the new
Neutralizing Antibody Assay for HIV-1 in A3R5 Cells to its
laboratories. In addition, this technology transfer process could
serve as a guideline for transferring other standardized assay
technologies to laboratories worldwide.
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